



JKUT MEETING RESULT 01/2025

NEWLY APPROVED DRUGS IN HUMS FORMULARY

DRUGS	<div>EMPAGLIFLOZIN 12.5MG / METFORMIN HCL 1000MG TABLET</div> <div></div>	<div>SITAGLIPTIN PHOSPHATE 50MG / METFORMIN HCL 500MG EXTENDED RELEASE TABLET</div> <div></div>	<div>SEMAGLUTIDE 3MG, 7MG, 14MG TABLETS</div> <div></div>
INDICATION & DOSE	<div>Indication: As an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 Diabetes Mellitus</div> <div>Dose: 1-2 tablets daily in divided doses.</div>	<div>Indication: As an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 Diabetes Mellitus</div> <div>Dose: 1-2 tablets once daily.</div>	<div>Indication: Treatment of adults with insufficiently controlled Type 2 Diabetes Mellitus to improve glycaemic control as an adjunct to diet and exercise as monotherapy</div> <div>Dose: Initially 3mg OD for 1 month, then 7mg OD (maintenance dose) for at least 1 month, can be increased to 14mg OD (maintenance dose) to further improve glycaemic control.</div>
APPROVED POLICY	<div>Prescriber Category: A* (Internal Medicine & FMS)</div>	<div>Prescriber Category: A* (Internal Medicine & FMS)</div>	<div>Prescriber Category: A* (Internal Medicine & FMS)</div>

DRUGS	<div></div> <div>INSULIN ASPART 100IU/ML INJECTION</div>	<div></div> <div>INSULIN DEGLUDEC 70% AND INSULIN ASPART 30% 100IU/ML INJECTION</div>	<div>PREGABALIN 75MG CAPSULE (LYRICA)</div> <div></div>
INDICATION & DOSE	<div>Indication: DM in adults, adolescents & children ≥ 1 year old</div> <div>Dose: 0.5-1.0 IU/kg/day</div>	<div>Indication: DM in adults, adolescents & children ≥ 2 years old.</div> <div>Dose: The recommended total daily starting dose is 10 units with meal(s) followed by individual dosage adjustments.</div>	<div>Indication: Neuropathic pain in adults. Adjunctive therapy in adults with partial seizures with with or without secondary generalisation. Generalised anxiety disorder in adults, management of fibromyalgia.</div> <div>Dose: 150 to 600 mg per day given in either two or three divided doses.</div>
APPROVED POLICY	<div>Prescriber Category: A* (Internal Medicine & FMS)</div>	<div>Prescriber Category: A* (Internal Medicine & FMS)</div>	<div>Prescriber Category: A* (Internal Medicine)</div>



JKUT MEETING RESULT 01/2025



NEWLY APPROVED DRUGS IN HUMS FORMULARY

DRUGS	<p>EPOETIN ALFA 2000IU INJECTION</p> 	<p>RIVAROXABAN 2.5MG TABLET</p> 
	<p>Indication:</p> <p>Anaemia associated with chronic renal failure in haemo- & predialysis adults & haemodialysis paediatric patients.</p> <p>Dose:</p> <p>Dosing is individualised and according to product insert / protocol.</p>	<p>Indication:</p> <p>Prevention of major atherothrombotic events in adult patients with coronary artery disease and/or symptomatic peripheral artery disease at high risk of ischaemic events</p> <p>Dose:</p> <p>2.5 mg twice daily</p>
	<p>Prescriber Category:</p> <p>A* (YKN Dialysis)</p>	<p>Prescriber Category:</p> <p>A* (Internal Medicine & FMS)</p>
DRUGS	<p>RIVAROXABAN 10MG TABLET</p> 	<p>RIVAROXABAN 20MG TABLET</p> 
	<p>Indication:</p> <p>Prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery.</p> <p>Dose:</p> <p>10mg once daily</p>	<p>Indication:</p> <p>Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.</p> <p>Dose:</p> <p>20mg once daily</p>
	<p>Prescriber Category:</p> <p>A* (Internal Medicine & FMS)</p>	<p>Prescriber Category:</p> <p>A* (Internal Medicine & FMS)</p>




JKUT MEETING RESULT 03/2025

NEWLY APPROVED DRUGS IN HUMS FORMULARY

DRUGS	<p>PROPRANOLOL 10MG TABLET</p> 	<p>SEMAGLUTIDE 2MG/1.5ML SOLUTION FOR INJECTION IN PRE-FILLED PEN</p> 
	<p>Indication:</p> <p>Hypertension, Angina pectoris, Post-myocardial infarction, Cardiac arrhythmias, Migraine prophylaxis, Hypertrophic obstructive cardiomyopathy</p> <p>Dose:</p> <p>Dosing is individualised and according to product insert / protocol.</p>	<p>Indication:</p> <p>Treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise.</p> <p>Off Label use: As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance.</p> <p>Dose:</p> <p>The starting dose is 0.25 mg semaglutide once weekly, maybe increased up to 1 mg once weekly to further improve glycaemic control.</p>
	<p>Prescriber Category:</p> <p>B (Standard)</p>	<p>Prescriber Category:</p> <p>A* (Internal Medicine & FMS)</p> <p>Off Label Use:</p> <p>A** (Internal Medicine – Obesity Clinic)</p>

NEWLY ADDED INDICATION

SEMAGLUTIDE 3MG, 7MG, 14MG TABLETS	EXISTING INDICATION	ADDED INDICATION
	<p>Indication:</p> <p>Treatment of adults with insufficiently controlled Type 2 Diabetes Mellitus to improve glycaemic control as an adjunct to diet and exercise as monotherapy</p>	<p>New Indication:</p> <p>Off Label use: As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI)</p> <p>1. ≥ 30 kg/m² (obesity), or</p> <p>2. ≥ 27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity e.g.dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia,obstructive sleep apnoea or cardiovascular disease.</p>
<p>DATE OF APPROVAL: 24 JULY 2025</p>		<p>Prescriber Category:</p> <p>Off Label Use: A** (Internal Medicine – Obesity Clinic)</p>



JKUT MEETING RESULT 03/2025

DRUG REMOVED FROM HUMS FORMULARY

NO	DRUG NAME	SUGGESTED ALTERNATIVE
1	Diclofenac Sodium SR 100mg Tablet	Diclofenac Sodium 50mg Tablet
2	Naproxen Sodium 275mg Tablet	Other available NSAIDs
3	Amoxicillin 125mg/Clavulanic Acid 31.25mg in 5ml Syrup	Amoxicillin + Clavulanic Acid 228mg/5ml Suspension (generic)
4	Valaciclovir 500mg Tablet	Acyclovir 200mg Tablet/Acyclovir 400mg Tablet
5	Salbutamol 2mg Tablet	Salbutamol 0.5% inhalation if requires nebulisation
6	Salbutamol 2mg/5ml Syrup	
7	Salbutamol Nebules Solution 2.5mg in 2.5ml (VENTOLIN)	Salbutamol 0.5% Inhalation
8	Lisinopril 10mg Tablet	Other available antihypertensives
9	Lisinopril 20mg Tablet	
10	Olmesartan Medoxomil 20mg + Hydrochlorothiazde 12.5mg Tablet	
11	Olmesartan Medoxomil 40mg + Hydrochlorothiazde 12.5mg Tablet	
12	Insect Repellant Cream	-
13	Olopatadine Hydrochloride 0.1% Ophthalmic Solution (PATANOL)	Olopatadine Hydrochloride 0.2% Ophthalmic Solution (PATADAY)
14	Timolol Maleate 0.5% Eye Drop	TIMO-COMOD
15	Gliclazide 80mg Tablet	Gliclazide 30mg MR Tab Gliclazide 60mg MR Tab
16	Glimepiride 2mg Tablet	
17	Insulin Lispro 25% + Lispro Protamin 75% 100 IU/ml KwikPen (Humalog Mix-25)	Novomix
18	Metformin HCl 850mg Tablet	Metformin 500mg Tablet
19	Metformin HCl XR 750mg Tablet	Metformin XR 500mg Tablet
20	Sodium Alginate 500 mg, Sodium Bicarbonate 213 mg & Calcium Carbonate 325 mg Suspension (GAVISCON DOUBLE ACTION)	MMT Syrup



JKUT MEETING RESULT 03/2025

DRUG REMOVED FROM HUMS FORMULARY

NO	DRUG NAME	SUGGESTED ALTERNATIVE
21	Pantoprazole 20mg Tablet	Pantoprazole 40mg Tablet
22	Gingko Biloba 120mg Tablet (TEBONIN FORTE)	Patient self-purchase from HUMS Pharma
23	Mixed Tocotrienols 200mg Softgel (TOCOVID)	
24	Darbepoetin Alfa 20mcg/0.5ml Injection	Erysaa / Mircera
25	Darbepoetin Alfa 40mcg/0.5ml Injection	
26	Darbepoetin Alfa 120mcg/0.5ml Injection	
27	Vecuronium 4mg/ml Injection	Suxamethonium, atracurium and rocuronium
28	Cyanoacrylate Tissue Adhesive	Move to list of consumable items
29	Dichlorotab Effervescent Disinfectant Tablet	
30	Formalin Solution	
31	Gigasept Solution	
32	Liquid Paraffin BP/Mineral Oil USP	Internal use - Lactulose
33	Varenicline 0.5mg Tablet (CHAMPIX)	Nicotine gum / patch
34	Varenicline 1mg Tablet (CHAMPIX)	
35	Gamma Benzene Hexachloride 1% Lotion	Permethrin 1% w/v Lotion Permethrin 5% w/v Lotion Benzyl Benzoate 25% w/v Emulsion



EQUIVALENT DOSE OF
GLICLAZIDE STANDARD-RELEASE TABLET VS
GLICLAZIDE MODIFIED-RELEASE TABLET

Generally, total daily dose of
T.Gliclazide 80mg (40mg BD) = T.Gliclazide MR 30mg

GLICLAZIDE STANDARD-RELEASE TABLET (MAX DOSE = 160MG BD)	GLICLAZIDE MODIFIED-RELEASE TABLET (MAX DOSE = 120MG OD)
T. Gliclazide 40mg BD	T. Gliclazide MR 30mg OD
T. Gliclazide 80mg BD	T. Gliclazide MR 60mg OD
T. Gliclazide 120mg BD	T. Gliclazide MR 90mg OD
T. Gliclazide 160mg BD	T. Gliclazide MR 120mg OD

Reference:

MIMS Malaysia. (2025). Gliclazide. In MIMS Online. Retrieved September 4, 2024, from <https://www.mims.com/malaysia/drug/info/gliclazide>.

Published by:
**DRUG INFORMATION CENTRE
PHARMACY DEPARTMENT
HOSPITAL UNIVERSITI MALAYSIA SABAH
12 SEPTEMBER 2025**

EDITORIAL BOARD:
EN. SIAU HONG SHIN
PN. EIRLEEZA BINTI AWANG ABU BAKAR
PN. JALIHAN BINTI IDRIS @ EDRIS (ADVISOR)
dis.hpums@ums.edu.my